516 results
EuroPCR 2021 Hotlines / Late-Breaking Trials in imaging: CASTLE, CLI-OPCI, FORZA, ILUMIEN-IV, CLI-OPCI II, and more!
27 May 2021 – From EuroPCR 2021
Find out more about various studies & registries in imaging:
- A randomized study comparing imaging guided implantation of Orsiro and Xience: the CASTLE study
- Impact of different optimal stent implantation definitions in OCT-guide PCI
- Risk-stratification in ACS by comprehensive morphofunctional assessment with OCT
- 7.5 years follow-up after OCT-guided PCI: report...
EuroPCR 2021 Hotlines / Late-Breaking Trials in physiology: FAST II, TARGET FFR, P3, OLV Pullback, France PCI, and more!
27 May 2021 – From EuroPCR 2021
Find out more about various studies & registries in imaging:
- Angiography based Fractional Flow Reserve: the FAST II trial
- Instantaneous wave-free ratio for the assessment of nonculprit lesions
- Capacity of the PPG to predict functional revascularisation
- Clinical impact of FFR guided PCI
Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction - FLOWER-MI
26 May 2021
This investigator-initiated randomised, open-label, multicentre trial compares FFR versus angiography guided strategies for treating non-culprit lesions in patients presenting with STEMI and multivessel coronary artery disease. The results of this study were released during ACC.21.
Reviewer
Reviewer
EuroPCR 2021 Hotlines / Late-Breaking Trials in ACS: COOL AMI EU pivotal rial and more!
21 May 2021 – From EuroPCR 2021
Find out more about various studies & registries in ACS:
- COOL AMI EU pivotal trial
- Complete versus incomplete revascularization in NSTEMI patients
- Non-hyperaemic IMRangio and long-term clinical outcome in STEMI
EuroPCR 2021 Hotlines / Late-Breaking Trials: MAGSTEMI, France ABSORB, FUTURE-II, STRATEGY-IT, AIDA, and PRAGUE 22
21 May 2021 – From EuroPCR 2021
Find out more about various studies & registries in BRS/BVS:
- Magnesium-based Bioresorbable Scaffold in STEMI: 2 years results
- France Absorb registry: final five years follow-up
- A randomized trial of thinner-strut sirolimus-eluting BRS in de novo lesions
- Three-year follow-up of the prospective bvs stemi strategy-it study
- Final five-year results of AIDA trial
- Bioresorbable...
EuroPCR 2021 Hotlines / Late-Breaking Trials: POEM, CEL-02, and PENDULUM
21 May 2021 – From EuroPCR 2021
Find out more about various studies & registries in drugs & devices:
- POEM study: 1-month DAPT after PCI with bioresorbable-polymer EES in HBR patients
- CEL-O2 trial: a novel rapid glycoprotein IIb/IIIa inhibitor(RUC-4) for STEMI patients
- PENDULUM registry study: impact of Clinical Outcomes and Platelet Reactivity After Percutaneous Coronary
Managing a patient with STEMI and bystander disease in the pandemic (Part 2) - Session with LIVE case
20 May 2021 – From EuroPCR 2021
Watch this session if you want to be updated on developments in treatment of ACS and STEMI, and to discuss diagnosis and treatment for bystander disease.
This session was originally presented during EuroPCR 2021.
Managing a patient with STEMI and bystander disease in the pandemic (Part 1) - Session with LIVE demonstration
20 May 2021 – From EuroPCR 2021
Watch this session if you want to be updated on developments in treatment of ACS and STEMI and to discuss diagnosis and treatment for bystander disease.
This session was originally presented during EuroPCR 2021.
EuroIntervention - Most discussed papers of the year
19 May 2021 – From EuroPCR 2021
Watch this session if you want to know the top 3 most discussed papers of the year which concern management of myocardial revascularisation failure, the impact of COVID-19 pandemic on interventional cardiology practice and Ischaemia witch non-obstructive coronary arteries.
This session was originally presented during EuroPCR 2021.
Importance of extensive revascularisation and timing of mechanical circulatory support
19 May 2021 – From EuroPCR 2021
Watch this session presented by Carsten Tschöpe, Francesco Burzotta and Nikos Werner in order to learn and see real-world revascularisation strategies with mechanical circulatory support, and to know more about the importance of extensive revascularisation and of the timing of mechanical circulatory support in high-risk interventions and cardiogenic shock.
